Not-for-profit research partnership TB Alliance has won a A$17 million (US$11.1 million) grant from the Australian government to continue its work combating tuberculosis.
The funding will contribute towards the completion of a Phase II trial, NC-009, which is taking place in multiple countries around the world and which began enrollment late last year.
The study is testing the safety and efficacy of a combination of TBAJ-876, pretomanid and linezolid, for its potential to shorten and improve treatment for both drug-sensitive and drug-resistant tuberculosis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze